ABACO CAPITAL PLC 
By Oxford Pharmascience Group plc
("Oxford Pharmascience" or "the Company")
Director's interest - Grant of options
Oxford Pharmascience announces that it has granted options over a total of 5,000,000 ordinary shares of 0.1 pence each in the Company to Nigel Theobald, Chief Executive Officer. The 5,000,000 share options were granted under the Company's EMI Share Option Plan 2010. The exercise price of the options is 2.68 pence per share and the options are subject to performance conditions.
2,500,000 of the share options vest between 12 months from the date of grant and the tenth anniversary from the date of grant and 2,500,000 of the share options vest between 24 months from the date of grant and the tenth anniversary from the date of grant.
Enquiries:
Oxford Pharmascience Group plc
Marcelo Bravo +44 1865 854 874
N+1 Singer
Shaun Dobson/Jenny Wyllie +44 207 496 3000
About Oxford Pharmascience Group Plc
Oxford Pharmascience Group Plc develops advanced yet practical pharmaceutical technologies to enable reformulation that adds value to off patent and soon to be off patent drugs. The Company does not manufacture or sell its own pharmaceutical products but instead seeks to license its technologies to a network of partners, mainly leading pharmaceutical companies with Rx (prescription) and OTC (Over the Counter) branded portfolios. These partners use our technologies to reposition their products helping them sustain market share and profitability by delivering improved health outcomes and/or clinical profiles via reformulated versions of the same API (active pharmaceutical ingredient).
Oxford Pharmascience Group Plc develops platform technologies that have application across multiple drug categories and can be leveraged across a broad range of reformulation problems. This business model allows us to provide solutions across the industry and fund the ongoing development of cutting edge technologies to better serve the needs of our partners. The partner companies who adopt our technology pay an up-front license fee followed by development milestone payments and then royalties on finished products sold using the technology. OXP invests the upfront licence fee to optimise product development and to ensure seamless technology transfer to the pharmaceutical partner.
This information is provided by RNS
|
distributed by
|
